Axsome Therapeutics (AXSM) Operating Income (2022 - 2025)
Historic Operating Income for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$46.1 million.
- Axsome Therapeutics' Operating Income rose 2637.17% to -$46.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$212.4 million, marking a year-over-year increase of 3063.07%. This contributed to the annual value of -$280.6 million for FY2024, which is 2102.32% down from last year.
- As of Q3 2025, Axsome Therapeutics' Operating Income stood at -$46.1 million, which was up 2637.17% from -$36.7 million recorded in Q2 2025.
- Over the past 5 years, Axsome Therapeutics' Operating Income peaked at -$6.4 million during Q1 2023, and registered a low of -$98.3 million during Q4 2023.
- Moreover, its 4-year median value for Operating Income was -$59.9 million (2022), whereas its average is -$55.5 million.
- Its Operating Income has fluctuated over the past 5 years, first skyrocketed by 8335.29% in 2023, then tumbled by 95545.97% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' Operating Income stood at -$59.9 million in 2022, then plummeted by 64.01% to -$98.3 million in 2023, then increased by 26.11% to -$72.6 million in 2024, then skyrocketed by 36.5% to -$46.1 million in 2025.
- Its Operating Income stands at -$46.1 million for Q3 2025, versus -$36.7 million for Q2 2025 and -$57.0 million for Q1 2025.